- Home
- OPFI vs CRDF Comparison
OPFI vs CRDF Comparison
Compare OPFI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- CRDF
- Stock Information
- Founded
- OPFI 2009
- CRDF 1999
- Country
- OPFI United States
- CRDF United States
- Employees
- OPFI N/A
- CRDF N/A
- Industry
- OPFI Finance: Consumer Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPFI Finance
- CRDF Health Care
- Exchange
- OPFI Nasdaq
- CRDF Nasdaq
- Market Cap
- OPFI 205.2M
- CRDF 185.6M
- IPO Year
- OPFI N/A
- CRDF N/A
- Fundamental
- Price
- OPFI $8.08
- CRDF $2.94
- Analyst Decision
- OPFI Buy
- CRDF Strong Buy
- Analyst Count
- OPFI 2
- CRDF 4
- Target Price
- OPFI $7.50
- CRDF $12.00
- AVG Volume (30 Days)
- OPFI 1.0M
- CRDF 1.5M
- Earning Date
- OPFI 05-07-2025
- CRDF 05-01-2025
- Dividend Yield
- OPFI 3.14%
- CRDF N/A
- EPS Growth
- OPFI N/A
- CRDF N/A
- EPS
- OPFI 0.36
- CRDF N/A
- Revenue
- OPFI $276,770,000.00
- CRDF $683,000.00
- Revenue This Year
- OPFI $112.50
- CRDF N/A
- Revenue Next Year
- OPFI $7.84
- CRDF N/A
- P/E Ratio
- OPFI $22.13
- CRDF N/A
- Revenue Growth
- OPFI 22.23
- CRDF 39.96
- 52 Week Low
- OPFI $2.56
- CRDF $2.01
- 52 Week High
- OPFI $17.73
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- OPFI 39.26
- CRDF 44.86
- Support Level
- OPFI $7.81
- CRDF $2.73
- Resistance Level
- OPFI $8.49
- CRDF $3.04
- Average True Range (ATR)
- OPFI 0.60
- CRDF 0.23
- MACD
- OPFI 0.00
- CRDF 0.05
- Stochastic Oscillator
- OPFI 23.28
- CRDF 79.86
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.